PDS Biotechnology Corporation
PDSBPDS Biotechnology is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted cancer and infectious disease immunotherapies.
Table of contents
Earnings
Next report
Aug 12, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
PDS Biotechnology is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted cancer and infectious disease immunotherapies. The company leverages its proprietary Versamune and Infectimune T cell-activating platforms to induce high-quality, potent CD8 killer and CD4 helper T cells. Its core value proposition lies in overcoming the immune-suppressive tumor microenvironment to treat various cancers and providing durable protection against infectious pathogens.
A clinical-stage innovator utilizing proprietary lipid nanoparticle technology to differentiate its immunotherapies from standard-of-care checkpoint inhibitors.
Questions, answered.
- What is PDS Biotechnology Corporation's market cap?
- PDS Biotechnology Corporation (PDSB) has a market capitalization of $43.9M and trades on NASDAQ.
- Who are PDS Biotechnology Corporation's competitors?
- PDS Biotechnology Corporation's key competitors include Inovio Pharmaceuticals, Moderna, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does PDS Biotechnology Corporation partner with?
- PDS Biotechnology Corporation's notable partners include Merck & Co., Merck KGaA, National Cancer Institute, and others.
- Where is PDS Biotechnology Corporation headquartered?
- PDS Biotechnology Corporation is headquartered in United States of America and employs approximately 25 people. It has been publicly traded since 2015.